Pyrotinib with chemotherapy may improve outcomes in patients with pretreated HER2-positive breast cancer
South Korea’s daily virus jump exceeds 7,000 for 1st time
8 December 2021Researchers reveal inner nuclear membrane protein as positive regulator in breast cancer metastasis
8 December 2021Pyrotinib with chemotherapy may improve outcomes in patients with pretreated HER2-positive breast cancer
Among patients with previously treated HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had longer overall survival than those who received lapatinib (Tykerb) plus capecitabine, according to updated results from the phase III PHOEBE trial presented at the San Antonio Breast Cancer Symposium, held December 7–10, 2021.
